UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549





                                    FORM 8-K

                                 CURRENT REPORT

                         Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934


       Date of Report (Date of earliest event reported): October 27, 2003


                         SCICLONE PHARMACEUTICALS, INC.
             (Exact name of registrant as specified in its charter)


         Delaware                        0-19825                 94-3116852
(State or other jurisdiction of   (Commission File Number)    (I.R.S. Employer
       incorporation)                                        Identification No.)



                      901 Mariner's Island Blvd., Suite 205
                           San Mateo, California 94404
               (Address of principal executive offices) (Zip Code)



       Registrant's telephone number, including area code: (650) 358-3456





Item 7.           Financial Statements and Exhibits.

         (c)      Exhibits.

         Exhibit  Description
         -------  -----------

         99.1     Press Release issued by SciClone Pharmaceuticals, Inc., dated
                  October 27, 2003, announcing financial results for the third
                  quarter of fiscal year 2003.


Item 12.          Results of Operations and Financial Condition.

     On October 27, 2003, SciClone Pharmaceuticals, Inc. (the "Company") issued
a press release announcing its financial results for the third quarter of fiscal
year 2003. A copy of the Company's press release is attached hereto as Exhibit
99.1 and incorporated herein by reference. The information in this Current
Report on Form 8-K, including the exhibit, is furnished pursuant to Item 12 and
shall not be deemed "filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities under
that Section. Furthermore, the information in this Current Report on Form 8-K,
including the exhibit, shall not be deemed to be incorporated by reference into
the filings of the Company under the Securities Act of 1933, as amended, or the
Securities Act of 1934, as amended.


                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



                         SCICLONE PHARMACEUTICALS, INC.


Dated:  October 27, 2003

         /s/Richard A. Waldron
         -----------------------------
         Richard A. Waldron
         Chief Financial Officer